TYK2 and psoriasis vulgaris: By selectively inhibiting TYK2, deucravacitinib disrupts these signaling pathways, mitigating keratinocyte hyperproliferation and excessive inflammation, making it an effective treatment for psoriasis vulgaris [15,16].